Increase in tuberculin skin test converters among health care workers after a change from Tubersol to Aplisol


      Comparability of the 2 commercially available tuberculin skin testing (TST) preparations, Aplisol (Parkdale Pharmaceuticals, Inc, Rochester, MI) and Tubersol (Aventis Pasteur, Inc, Swiftwater, PA), remains uncertain, particularly in groups that undergo repeated testing, such as health care workers.


      Data from the annual tuberculosis screening program for health care workers at the Kennedy Krieger Institute in Baltimore, Maryland, were analyzed. Conversion rates during 1997-2003 in workers screened with Tubersol (n = 8897 screenings) were compared with 1203 workers who underwent screening with Aplisol in 2004. Repeat testing with Tubersol was examined in those who converted in 2004 with Aplisol.


      Annual TST conversion rates ranged from 0.3% to 0.9% between 1997 and 2003 using Tubersol. After switching to Aplisol in 2004, the TST conversion rate significantly increased to 2% (P < .001). Among 24 health care workers who were converters with Aplisol in 2004, only 6 of 23 (26%) were converters on repeat testing with Tubersol (1 declined retesting). None of the apparent converters (n = 24) had radiographic evidence of Mycobacterium tuberculosis infection, and there was no epidemiologic evidence of transmission. Reclassification based on Tubersol testing in 2004 resulted in conversion rates comparable with previous years.


      We conclude that the change from Tubersol to Aplisol resulted in falsely elevated conversion rates. Our results support the guidelines from the Centers for Disease Control and Prevention recommendations that 1 product should be used consistently in populations undergoing periodic testing.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jensen P.A.
        • Lambert L.A.
        • Iademarco M.F.
        • Ridzon R.
        • for the Centers for Disease Control and Prevention
        Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care settings.
        MMWR Recomm Rep. 2005; 54: 1-141
        • Grabau J.C.
        • Hughes S.E.
        • Foster E.A.
        • Kearns C.H.
        • Klopf L.
        False-positive tuberculin skin tests in a state prison system.
        Int J Tuberc Lung Dis. 2003; 7: 93-97
        • Rupp M.E.
        • Schultz A.W.
        • Davis J.C.
        Discordance between tuberculin skin test results with two commercial purified protein derivative preparations.
        J Infect Dis. 1994; 169: 1174-1175
        • Duchin J.S.
        • Jereb J.A.
        • Nolan C.M.
        • Smith P.
        • Onorato I.M.
        Comparison of sensitivities to two commercially available tuberculin skin test reagents in persons with recent tuberculosis.
        Clin Infect Dis. 1997; 26: 661-663
        • Sepkowitz K.A.
        • Fella P.
        • Rivera P.
        • Villa N.
        • DeHovitz J.
        Prevalence of PPD positivity among new employees at a hospital in New York City.
        Infect Control Hosp Epidemiol. 1995; 16: 344-347
        • Lanphear B.P.
        Potential consequences of using Aplisol tuberculin tests in prior epidemic populations.
        Infect Control Hosp Epidemiol. 1995; 16: 255
        • Shands J.W.
        • Boeff D.
        • Fauerbach L.
        • Gutekunst R.R.
        Tuberculin testing in a tertiary hospital: product variability.
        Infect Control Hosp Epidemiol. 1994; 15: 758-760
        • Lanphear B.P.
        • Linnemann C.C.
        • Cannon C.G.
        A high false-positive rate of tuberculosis associated with Aplisol: an investigation among health care workers.
        J Infect Dis. 1994; 169: 703-704
        • Blackshear J.
        • Bravo E.
        • Gesink D.
        • Davies S.F.
        • Iber C.
        • Johnson J.R.
        False-positive skin tests with Parke-Davis Aplisol.
        Am Rev Respir Dis. 1983; 127: 254
        • Tat D.
        • Polenakovik H.
        • Herchline T.
        Comparing interferon-γ release assay with tuberculin skin test readings at 48-72 hours and 144-168 hours with use of two commercial reagents.
        Clin Infect Dis. 2005; 40: 246-250
        • Blumberg H.M.
        • White N.
        • Parrot P.
        • Gordon W.
        • Hunter M.
        • Ray S.
        False-positive tuberculin skin test results among health care workers.
        JAMA. 2000; 283: 2793
      1. Diagnostic standards and classification of tuberculosis in adults and children. This official statement of the American Thoracic Societ and the Centers for Disease Control and Prevention was adopted by the ATS board of directors, July 1999.
        Am J Respir Crit Care Med. 2000; 161: 1376-1395
      2. Maryland Department of Health and Mental Hygiene. Maryland tuberculosis incidence by geographic areas and demographic features, 1995-2004. Available at: Accessed February 7, 2006.

        • Larsen N.M.
        • Biddle C.L.
        • Sotir M.J.
        • White N.
        • Parrott P.
        • Blumberg H.M.
        Risk of tuberculin skin test conversion among health care workers: occupational versus community exposure and infection.
        Clin Infect Dis. 2002; 35: 796-801
        • Menzies D.
        • Fanning A.
        • Yuan L.
        • Fitzgerald M.
        Tuberculosis among health care workers.
        N Engl J Med. 1995; 332: 92-98
        • Garber G.
        • San Gabriel P.
        • Lamber L.
        • Saiman L.
        A survey of latent tuberculosis infection among laboratory health care workers in New York City.
        Infect Control Hosp Epidemiol. 2003; 24: 801-806
        • Villarino M.E.
        • Burman W.
        • Wang Y.C.
        • Lundergan L.
        • Catanzaro A.
        • Block N.
        • et al.
        Comparable specificity of 2 commercial tuberculin reagents in person at low risk for tuberculosis infection.
        JAMA. 1999; 281: 169-171